ALZpath Inc., an Alzheimer’s Disease Diagnostics and Patient Services Company Announces Novel Validated and Scalable Assay for Detection of Phosphorylated Tau 217 in Blood

Carlsbad, Calif., Nov. 28, 2022 – ALZpath, Inc. announced today the launch of its first diagnostic assay for detection of phosphorylated tau 217 (pTau217) in blood. pTau217 is widely considered to be one of the leading transformative Alzheimer’s disease (AD) diagnostic biomarkers by enabling earlier and more accurate AD diagnoses, better stratifying patients for clinical […]